ImmuCell Corporation Segment Expenditure Addition To Long Lived Assets
ImmuCell Corporation (ICCC) reported Segment Expenditure Addition To Long Lived Assets of $733.94 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentExpenditureAdditionToLongLivedAssets · last filed 2026-08-13
- ImmuCell Corporation segment expenditure addition to long lived assets for the quarter ending 2026-06-30 was $733.94K, a 373.03% increase year-over-year.
- ImmuCell Corporation segment expenditure addition to long lived assets for the quarter ending 2026-03-31 was $177.23K, a 46.14% decline year-over-year.
- ImmuCell Corporation segment expenditure addition to long lived assets for the quarter ending 2025-12-31 was $172.31K, a 12.19% decline year-over-year.
- ImmuCell Corporation segment expenditure addition to long lived assets for the quarter ending 2025-09-30 was $593.92K, a 571.77% increase year-over-year.
- ImmuCell Corporation segment expenditure addition to long lived assets for fiscal 2025 was $1.25M, a 168.49% increase from fiscal 2024.
- ImmuCell Corporation segment expenditure addition to long lived assets for fiscal 2024 was $465.73K.
| Period end | Segment Expenditure Addition To Long Lived Assets 3 month | Segment Expenditure Addition To Long Lived Assets 6 month | Segment Expenditure Addition To Long Lived Assets 9 month | Segment Expenditure Addition To Long Lived Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $733.94K 10-Q · filed 2026-08-13 | $911.17K 10-Q · filed 2026-08-13 | $1.08M derived: sum of 3 quarters · filed 2026-08-13 | $1.68M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $177.23K 10-Q · filed 2026-05-14 | $349.54K derived: sum of 2 quarters · filed 2026-05-14 | $943.46K derived: sum of 3 quarters · filed 2026-05-14 | $1.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $172.31K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $766.23K derived: sum of 2 quarters · filed 2026-03-30 | $921.39K derived: sum of 3 quarters · filed 2026-08-13 | $1.25M 10-K · filed 2026-03-30 |
| 2025-09-30 | $593.92K 10-Q · filed 2025-11-13 | $749.08K derived: sum of 2 quarters · filed 2026-08-13 | $1.08M 10-Q · filed 2025-11-13 | $1.27M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $155.16K 10-Q · filed 2026-08-13 | $484.21K 10-Q · filed 2026-08-13 | $680.42K derived: sum of 3 quarters · filed 2026-08-13 | $768.84K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $329.05K 10-Q · filed 2026-05-14 | $525.27K derived: sum of 2 quarters · filed 2026-05-14 | $613.68K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $196.22K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $284.63K derived: sum of 2 quarters · filed 2026-03-30 | $465.73K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $88.41K 10-Q · filed 2025-11-13 | $269.51K 10-Q · filed 2025-11-13 | ||
| 2023-12-31 | $1.89M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |